Hannah N. Coleman

Federal Grant PI

Role not yet determined Is this you? Add your title

UAMS

Also affiliated: Center for Infectious Disease Research (2003); Arkansas Children's Hospital (2007); Johns Hopkins University (2003); Arkansas Children's Research Institute (2007); University of Missouri (2003)

14 h-index 30 pubs 706 cited

Research Areas

Biomedical Subjects

Links

Lab Website

OverviewAI-generated summary

Hannah Coleman's research program focuses on understanding and enhancing immune responses to human papillomaviruses (HPVs), particularly in the context of cervical cancer prevention and treatment. She is the Principal Investigator on a renewal grant from the NIH/National Cancer Institute, "Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal," which has received $727,264 in funding. Her work has investigated therapeutic vaccines for cervical intraepithelial neoplasia (CIN), exploring peptide-based HPV therapeutic vaccines like PepCan and their adjuvant effects.

Coleman's publications also indicate an interest in advanced computational methods applied to medical imaging and diagnostics. She has contributed to studies utilizing physics-informed deep generative learning for quantitative assessment of the retina and harnessing machine learning for microscopic vessel segmentation in pulmonary fibrosis. Her research also extends to the analysis of biological samples, including the evaluation of DNA extraction protocols for cervical cytology specimens and the prediction of patient outcomes using urine metabolites.

Her scholarly contributions include 44 publications with an h-index of 15 and 771 total citations. Coleman actively collaborates with researchers at the University of Arkansas for Medical Sciences, including Mayumi Nakagawa, Takeo Shibata, Yong‐Chen Lu, and Teresa Evans, with whom she has co-authored multiple publications.

Metrics

h-index: 14
Publications: 30
Citations: 706

Selected Publications

A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or Candida (2025)

medRxiv 3 citations DOI OpenAlex
Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus Candida adjuvant alone in treating cervical intraepithelial neoplasia 2/3. (2024)

Journal of Clinical Oncology 2 citations DOI OpenAlex
A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3). (2023)

Journal of Clinical Oncology 2 citations DOI OpenAlex
Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed (2021)

Frontiers in Immunology 14 citations DOI OpenAlex
Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota (2021)

PLoS ONE 12 citations DOI OpenAlex
Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed (2020)

bioRxiv (Cold Spring Harbor Laboratory) DOI OpenAlex
Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota (2020)

bioRxiv (Cold Spring Harbor Laboratory) 4 citations DOI OpenAlex
Cervical Microbiome and Response to a Human Papillomavirus Therapeutic Vaccine for Treating High-Grade Cervical Squamous Intraepithelial Lesion (2019)

Integrative Cancer Therapies 16 citations DOI OpenAlex
An assessment of Oxford Nanopore sequencing for human gut metagenome profiling: A pilot study of head and neck cancer patients (2019)

Journal of Microbiological Methods 18 citations DOI OpenAlex
Cervical microbiome role in outcomes of therapeutic HPV vaccination for cervical intraepithelial neoplasia. (2018)

Journal of Clinical Oncology 3 citations DOI OpenAlex
A novel prostate cancer immunotherapy using prostate-specific antigen peptides and Candida skin test reagent as an adjuvant (2018)

SAGE Open Medicine 2 citations DOI OpenAlex
A novel prostate cancer immunotherapy using prostate specific antigen peptides and Candida skin test reagent as an immunostimulant. (2016)

Journal of Clinical Oncology DOI OpenAlex
Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination (2016)

Cancer Immunology Immunotherapy 63 citations DOI OpenAlex
A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3. (2015)

Journal of Clinical Oncology DOI OpenAlex
A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3 (2015)

OncoImmunology 50 citations DOI OpenAlex